Imaging response in neuroendocrine tumors treated with targeted therapies: The experience of sunitinib

Targeted Oncology

Volumn 7, Issue 2, 2012, Pages 127-133

  Faivre, Sandrine ^a   Ronot, Maxime ^a   Dreyer, Chantal ^a   Serrate, Camille ^a   Hentic, Olivia ^a   Bouattour, Mohamed ^a   Bruno, Onorina ^a   Couvelard, Anne ^b   Vilgrain, Valérie ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Angiogenesis; Choi; Hypodensity; Necrosis; RECIST

Indexed keywords

EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; MICROVASCULATURE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84865725751     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0216-y     Document Type: Review

References (26)

1. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056 (Pubitemid 32267975)
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
3. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
4. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
5. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imati-nib: randomised trial. Lancet 364:1127-1134 (Pubitemid 39296599)
6. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632 (Pubitemid 351264358)
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
8. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-1764 (Pubitemid 46797958)
9. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759 (Pubitemid 46797957)
10. Faivre S, Sablin MP, Dreyer C, Raymond E (2010) Novel antican-cer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin N Am 39:811-826
11. Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
12. Yao JC et al (2011) Everolimus for advanced pancreatic neuroen-docrine tumors. N Engl J Med 364:514-523
13. Couvelard A et al (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92:94-101 (Pubitemid 40188441)
14. Rodallec M et al (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77-85
15. Dromain C, de Baere T, Lumbroso J et al (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23:70-78 (Pubitemid 41702624)
16. Faivre S et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35 (Pubitemid 46630490)
17. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745 (Pubitemid 47338181)
18. Faivre S, Raymond E, Boucher E et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794-800
19. Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E (2011) Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 17:4504-4512
20. Faivre SJ, Bouattour M, Dreyer C, Raymond E (2009) Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol 27:e248-e250
21. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027-3035
22. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT (2009) Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 35:309-321
23. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300 (Pubitemid 46630787)
24. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430 (Pubitemid 32844200)
25. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60
26. Wassermann J, Bouattour M, Bruno O, Serrate C, Larroque B, Castera L, Dreyer C, Sablin MP, Colichi C, Vilgrain V, Belghiti J, Raymond E, Faivre S (2011) Blinded independent central response assessment using RECIST, mRECIST, and Choi criteria in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). Proc ILCA Meeting